This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Pluristem Appoints Diabetic Neuropathy And Vascular Disease Expert, Dr. Aristidis Veves, To Its Scientific Advisory Board

Pluristem Therapeutics Inc. (NasdaqCM: PSTI) (DAX: PJT) today announced that it appointed Dr. Aristidis Veves to the company’s Scientific Advisory Board.

Dr. Veves brings more than 30 years of experience in the field of diabetic neuropathy and vascular disease. An expert in diabetic foot problems and vascular reactivity, Dr. Veves is the research director of the Joslin-Beth Israel Deaconess Foot Center and of the Microcirculation Lab, as well as an associate professor at Harvard Medical School. Dr. Veves’ research focuses on techniques that will identify patients at risk of developing diabetic foot problems at the early stages and therapeutic strategies that will prevent or slow the progression of this condition.

“Dr. Veves is a highly regarded thought leader in diabetic neuropathy and vascular disease, common in patients with Critical Limb Ischemia (CLI),” said Dr. Edwin Horwitz, Chairman of Pluristem’s Scientific Advisory Board. “His appointment to our advisory board will bring invaluable expertise and perspective in diabetic neurological conditions and wound care that will be necessary as Pluristem progresses through clinical studies with its placenta-derived cell therapies.”

Dr. Veves added, “Clinical results suggest that Pluristem’s product for peripheral artery disease, PLX-PAD, is potentially a safe, well tolerated and effective treatment for patients with diabetic foot and wound healing problems. I look forward to contributing to PLX-PAD’s clinical advancement as well as helping apply Pluristem’s technology to other neurological and wound care indications.”

Zami Aberman, Chairman and CEO of Pluristem, added: “We at Pluristem are extremely pleased that a researcher of Dr. Veves’ caliber is joining our Scientific Advisory Board and we believe his contributions will be valuable as we enter the neurologic and wound care markets with our PLX cells.”

About Pluristem

Pluristem is a clinical stage biotechnology company with patented technology for the development and manufacturing of standardized cell therapies derived from the human placenta. Pluristem’s proprietary and scalable PLX (PLacental eXpanded) cell product candidates are developed as readily available for the treatment of critical limb ischemia (CLI) and other diseases. In April 2010, Pluristem reported interim top-line results from Phase I clinical trials of PLX-PAD that demonstrated the cell therapy is potentially safe, well tolerated and effective in patients with critical limb ischemia (CLI).

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs